Tuesday, May 15, 2012

The Diabetes Drug Actos May Cause An Increased Risk of Bladder Cancer That Can Metastasize into Lung Cancer, Lymphatic Cancer, Liver Cancer, Bone Cancer, Prostate Cancer, Rectum Cancer, or Vaginal Cancer by Texas Actos Bladder Cancer Lawyer, Texas Diabetes Drug Cancer Lawyer, Diabetes Bladder Cancer Lawyer, and Texas Actos Cancer Death Lawyer

The Diabetes Drug Actos May Cause An Increased Risk of Bladder Cancer That Can Metastasize into Lung Cancer, Lymphatic Cancer, Liver Cancer, Bone Cancer, Prostate Cancer, Rectum Cancer, or Vaginal Cancer by Texas Actos Bladder Cancer Lawyer, Diabetes Drug Cancer Lawyer, Diabetes Bladder Cancer Lawyer, and Texas Actos Cancer Death Lawyer

Actos is a diabetes drug that has been prescribed to more than 10 million Americans since its approval for the treatment of type 2 diabetes.  It is an extremely profitable drug in that it has had multi-billion dollar annual global sales and has created large profits for its manufacturer.  Actos is manufactured by Takeda Pharmaceutical Co.  However, Actos has been linked to an increased risk of bladder cancer and has been pulled off the market in some European countries.  Actos is now under review by the FDA to determine if it will be pulled from the market or additional black box warnings will be added to the drug. 

Actos May Cause An Increased Risk of Bladder Cancer

Bladder Cancer is a form of cancer that begins in the lining of the bladder as a superficial tumor.  Bladder cancer can spread and metastasize into the lungs, liver, or bones resulting in serious health issues and even death. If left untreated bladder cancer can metastasize into lung cancer, lymphatic cancer, liver cancer, bone cancer, prostate cancer, rectum cancer, uterine cancer, and vaginal cancer. The most common symptom of bladder cancer is blood in the urine.  If you or a loved one have been taking Actos and have experienced blood in your urine, please contact your doctor immediately.  If you suffer from bladder cancer, lung cancer, lymphatic cancer, liver cancer, bone cancer, prostate cancer, rectum cancer, uterine cancer, or vaginal cancer and were taking Actos, please report the adverse facts.  If you have lost a person that you love from a bladder cancer, lung cancer, lymphatic cancer, liver cancer, bone cancer, prostate cancer, rectum cancer, uterine cancer, or vaginal cancer and your loved one was taking Actos, please report the adverse facts.

  Bladder Cancer Can Be Treated If Caught Early: People That Have Taken Actos or Are Taking Actos Should Be Aware of the Warning Signs of Bladder Cancer and Communicate with Their Doctor To Make Sure that They Are Both Aware of Any Symptoms by Texas Actos Bladder Cancer Lawyer, Texas Diabetes Drug Cancer Lawyer, Diabetes Bladder Cancer Lawyer, and Texas Actos Cancer Death Lawyer

Most bladder cancers begin in the transitional cells as transitional cell carcinoma, but can spread into nearby organs.  When bladder cancer spreads beyond the bladder, the malignant cells are frequently found in nearby lymph nodes and may have spread to other lymph nodes or other places including the lungs, liver, or bones.  The most common warning sign is blood in the urine. If there is enough blood to color the urine it may range from slightly rusty to deep red. Other symptoms may be pain during urination and frequent urination or feeling the need to urinate without results. 

Bladder cancer can be diagnosed into several different stages.  Stage 0 Bladder Cancer patients have noninvasive tumors that are only in the bladder lining; Stage I Bladder Cancer Patients have tumor(s) through the bladder lining, but the tumor(s) do not reach the muscle layer of the bladder; Stage II Cancer Patients have tumor(s) that go into the muscle layer of the bladder; Stage III Cancer Patients have tumor(s) that go past the muscle layer into tissue surrounding the bladder; and Stage IV Bladder Cancer Patients have tumor(s) that have spread to neighboring lymph nodes or to distant sites (metastatic disease) including the lungs, liver, bones, prostate, stomach, rectum, ureters, uterus,  and vagina.

Primary malignant bladder cancer can be classified by health care providers in several different categories depending on where it is found including the dome of urinary bladder; lateral wall of urinary bladder; anterior wall of urinary bladder; posterior wall of urinary bladder; bladder neck; ureteric orifice; urachus; and malignant neoplasm of contiguous or overlapping sites of bladder whose point of origin cannot be determined.

Carcinoma in situ is cancer that remains confined to the bladder lining. Bladder cancer may grow into or through the bladder wall and eventually into lymph nodes, lungs, liver, bones, or other nearby areas. 

Sunday, May 6, 2012

Popular Diabetes Treatments Could Trigger Pancreatitis and Pancreatic Cancer

Popular Diabetes Drugs and Treatments May Trigger Pancreatitis and Pancreatic Cancer: Januvia Users, Janumet Users, Victoza Users, and Byetta Users Should Be Aware of Potential Risks and Consult With Their Doctors Regarding Early Detection of Pancreas Problems and Pancreatic Cancer by Texas Diabetes Drug Cancer Lawyer Jason S. Coomer

Recent studies have indicated that a growing number of popular diabetes drugs including Januvia, Janumet, Victoza, and Byetta may cause pancreas problems including Pancreatitis and Pancreatic Cancer.  Diabetics that are taking Januvia, Janumet, Victoza, or Byetta should be aware of this potential health risk and be aware of symptoms that may suggest pancreas problems.  The warning signs of pancreatitis can include: 1) Upper abdominal pain that radiates into the back. Patients may describe this as a "boring sensation" that may be aggravated by eating, especially foods high in fat. 2) Swollen and tender abdomen 3) Nausea and vomiting 4) Fever  and 5) Increased heart rate.

Januvia Users, Janumet Users, Victoza Users, and Byetta users should be aware of these symptoms as well as any symptoms of pancreatic cancer including weight loss, dark urine and clay-colored stools, back pain, and jaundice.  Unfortunately, pancreatic cancer is difficult to diagnose, and the diagnosis is often made late in the course of the disease.  Early detection of pancreatic cancer is essential and will greatly improve a person's chances of surviving the disease.  Frequent and good communication with your doctor and awareness of you body are essential.  Additionally, make sure that all health care providers are aware that you are taking or have taken Januvia, Janument, Victoza, or Byetta.



Pancreatic cancer is the fourth leading cause of cancer death for both men and women and is one of the most deadly of all types of cancer. The diabetes drugs, Januvia and Janumet, may cause an increased risk of pancreatic cancer in patients using Januvia.

Popular Diabetes Treatment Could Trigger Pancreatitis, Pancreatic Cancer, Study Suggests

"ScienceDaily (Apr. 30, 2009) — A drug widely used to treat Type 2 diabetes may have unintended effects on the pancreas that could lead to a form of low-grade pancreatitis in some patients and a greater risk of pancreatic cancer in long-term users, UCLA researchers have found."


The consumer group, Public Citizen, has filed a petition with the Food and Drug Administration (FDA) requesting that the agency immediately remove the diabetes drug, Vicoza, from the market the increasingly prescribed diabetes drug Victoza (liraglutide [rDNA origin] injection) because it puts patients at higher risk of thyroid cancer, pancreatitis, serious allergic reactions and kidney failure that outweigh any documented clinical benefits.

Consumer Group to FDA: Take Victoza off the Market

"April 20, 2012 -- Public Citizen, the Washington, D.C.-based consumer advocacy group, is petitioning the FDA to immediately remove the type 2 diabetes drug Victoza (liraglutide) from the market. The petition claims that the injectable medication puts patients at risk of thyroid cancer, pancreatitis, serious allergic reactions, and kidney failure."


The injectable diabetes drug, Byetta (Exenatide), may cause an increased risk of pancreatic cancer in patients using ByettaIf you have lost a loved one from Pancreatic Cancer or have suffered acute pancreatitis, hemorrhagic pancreatitis, accute necrotizing pancreatitis, or pancreas cancer; and have been using Byetta (Exenatide), please report the adverse action to the prescribing medical doctor as soon as possible.

Popular diabetes drugs may raise pancreatic cancer risk – USATODAY.com

When compared to other treatments, the researchers found a sixfold increase of reported cases of pancreatitis (inflammation of the pancreas) linked to patients taking Januvia or Byetta; a 2.9-fold increase in reported cases of pancreatic cancer among those taking Byetta and a 2.7-fold increase of reported pancreatic cancers among Januvia users.
Fatal Diabetes Drug Lawsuits, Fatal Pancreatic Cancer Lawsuits, Diabetes Drug Cancer Lawsuits, and Diabetes Drug Pancreas Cancer Lawsuits

Drug manufacturers that were aware of their diabetes drug causing an increased risk of pancreatic cancer, pancreatitis, and pancreas cancer, but hid research linking this health risk can potentially be held liable by persons that have suffered pancreatitis and pancreatic cancer as well as the families of persons that have died from pancreatic cancer, pancreas cancer, thyroid cancer, or other cancers after using the drug.

The loss of a spouse, child, parent, or loved one to pancreatic cancer, pancreas cancer, or thyroid cancer can be devastating.  It is often worse to then find out that the loss of your loved one was unnecessary and could have been prevented if the defective diabetes drug manufacturer had properly disclosed the drug's potential dangers.  In these situations, where a loved one is lost from taking a defective diabetes drug and the drug company knew of the dangers of the drug, but marketed the diabetes drug as safe to make a profit; families are needed to stand up and make sure that the drug company does not get away with this and will not repeat this action to other families.

In fatal cancer diabetes drug lawsuits, diabetes drug attorneys will often work with families to seek compensation for the loss of their loved one.  Though no amount of money will ever replace or bring back their loved one.  The family will often need compensation to replace the lost earnings of their loved one or to pay medical expenses caused by the care needed by their lost loved one.   The fatal diabetes drug lawsuit will usually seek several elements of damages for the family of the deceased including their loss of love, companionship, comfort, assistance, protection, affection and care; the loss of financial support and lost benefits from the death; and loss of inheritance from an untimely death.  These fatal cancer diabetes drug lawsuits will also often include claims for what the decedent would have recovered had the person survived the cancer caused by the drug. These claims are through the decedent's estate and either go to their heirs or beneficiaries depending if the person had done any estate planning. These damages include expenses associated with the death including funeral costs, medical expenses prior to the death, and pain and suffering associated with the untimely death.  

Saturday, May 5, 2012

Novo Nordisk A/S : VictozaR label in the US updated to include data showing superior efficacy when compared to JanuviaR | Reuters

Novo Nordisk A/S : VictozaR label in the US updated to include data showing superior efficacy when compared to JanuviaR | Reuters


Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for VictozaR (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to JanuviaR (sitagliptin).

Group asks for withdrawal of Victoza diabetes drug | Reuters

Group asks for withdrawal of Victoza diabetes drug | Reuters


"(Reuters) - Watchdog group Public Citizen urged U.S. regulators to withdraw approval of Novo Nordisk's diabetes drug Victoza, saying it increases the risk of serious health problems like thyroid cancer and kidney failure. Public Citizen said the drug was approved in 2010 against the advice of three reviewers from the U.S. Food and Drug Administration, according a petition filed to the FDA on Thursday."

Monday, April 30, 2012

Janumet, Byetta, and Januvia May Cause Pancreatitis & Pancreas Cancer


Pancreatic cancer is the fourth leading cause of cancer death for both men and women and is one of the most deadly of all types of cancer. This year approximately 45,000 Americans will be diagnosed with pancreatic cancer and about 38,000 will die from it.  Unfortunately, pancreatic cancer is difficult to diagnose, and the diagnosis is often made late in the course of the disease.  Early detection of pancreatic cancer is essential and will greatly improve a person's chances of surviving the disease. 

The diabetes drugs, Januvia, Byetta, and Janumet may cause an increased risk of pancreatic cancer that have taken the diabetes drugs. As such, people that have taken Januvia, Byetta, and Janumet should be aware of the potential danger and be especially aware of the following symptoms: stomach pain, weight loss, dark urine and clay-colored stools, back pain, and jaundice.  Those taking Januvia, Byetta, and Janumet should seek advice from a qualified medical professional as to if they have any signs of pancreatic cancer, if these diabetes drugs are safe for them, and what symptoms they should be aware of to detect any early onset of pancreatic cancer.

The Diabetes Drug Market is Over $40 Billion Each Year and Growing Rapidly Januvia and Janumet had Annual Sales of $4.7 Billion in 2011

More than 300 million people worldwide suffer from diabetes, including about 30 million Americans.  In 2010, the global prevalence of diabetes was estimated to have reached 285 million and predicted to reach 438 million in 2030. The corresponding figures for North America were 37.4 million in 2010 and 53.2 million by 2030 and in Europe 55.2 million in 2010 and 66.2 million in 2030.  The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. 
 
In 2011, Januvia annual sales rose 39%, to $3.3 billion, from $2.4 billion the year before and $1.9 in 2009. Januvia along with its sister drug Janumet (a combination of Januvia and metformin) has combined for sales of $4.7 billion for 2011.  Sales of Januvia and Merck’s Januvia (sitagliptin) is approved in all major markets and have outdone initial estimates for the drugs.  

Merck’s Januvia (sitagliptin) is approved in all major markets and is the first in a new class of diabetic drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors.  It is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Saturday, April 21, 2012

Pharmas to Feel Lure of Deals in China

Pharmas to feel lure of deals BEIJING - China's drug market is primed for "explosive growth," making companies there attractive targets for drugmakers that will soon lose patents on their most popular treatments, according to KPMG LLP. Products worth more than $30 billion will lose patent cover this year, leading more drugmakers to look into buying or joining with companies in China, the world's third-biggest drug market, according to a KPMG report released on Wednesday.

Tuesday, April 17, 2012

Chinese Authorities are Suspending Sales of 13 Types of Capsules

Probe Launched into Pill Makers' Practices 

"Authorities are suspending sales of 13 types of capsules with reported chromium contamination and are checking the factories accused of producing them.The State Food and Drug Administration issued an urgent notice on Sunday to suspend sales until safety is tested.Police in Xinchang county, Zhejiang province, where China's largest capsule-manufacturing base in Ru'ao township is located, detained 22 people from four capsule factories on Monday, according to Xinhua News Agency.
Meanwhile, the administration and local authorities conducted inspections on 43 capsule factories in the county, closing those exposed by a China Central Television investigation to have made empty capsules using gelatin containing excessive chromium and selling them to pharmaceutical companies."